Pardoprunox

Drug Profile

Pardoprunox

Alternative Names: SLV-308; SME-308

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Solvay
  • Class Antidepressants; Antiparkinsonians; Anxiolytics; Benzoxazoles; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott
  • 11 Jun 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 13th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2009)
  • 19 Apr 2008 Efficacy and safety data from a phase II trial in Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top